Génome Canada

Génome Canada

July 09, 2010 15:47 ET

Genome Canada Appoints New Chair of its Science and Industry Advisory Committee

OTTAWA, CANADA--(Marketwire - July 9, 2010) - Genome Canada is pleased to announce the appointment of Dr. Jacques Simard (Ph.D.) as Chair of Genome Canada's Science and Industry Advisory Committee, effective June, 2010.

The Science and Industry Advisory Committee (SIAC) is a permanent committee of the Board of Directors, established to provide strategic advice on approaches and directions that contribute to the achievement of the corporation's goals.

Dr. Simard has been a member of Genome Canada's Board of Directors since 2005 and has served on a number of Board committees. He is taking the helm of the SIAC at a pivotal time in Genome Canada's history. In this 10th anniversary year, Genome Canada is taking the opportunity to reflect on the achievements of the past and ready itself for the opportunities of the future.

Dr. Simard holds a Canada Research Chair in Oncogenetics. He is currently a Professor in the Department of Molecular Medicine in the Faculty of Medicine at Laval University and Director of the Endocrinology and Genomics axis at the Centre Hospitalier Universitaire de Québec Research Centre. Since 2001 he has fulfilled the role of Director of the Interdisciplinary Health Research International Team on Breast Cancer Susceptibility which was recently renewed by the CIHR as a Clinical Research Network entitled "CIHR Team on Familial Risks of Breast Cancer". The network involves 25 scientists and clinicians from Canada, the USA, the UK and France.

In 1999, in acknowledgement of Dr. Simard's outstanding contributions, he received the Richard E. Weitzman Memorial Award, the most prestigious recognition for a scientist younger than 40, awarded by the Endocrine Society. He received the Prix d'excellence 2004 from the Fondation de la recherche sur les maladies infantiles and he is also a Fellow of the Canadian Academy of Health Sciences.

"On behalf of the Board of Directors of Genome Canada," said Dr. Thomas Caskey, M.D., and Genome Canada's Board Chair, "I am pleased to welcome Dr. Simard to the team in this new capacity as Chair of the SIAC. His enthusiasm and vision as well as his past experience working with the Board will ensure we receive forward-looking, useful advice from the SIAC in the years to come."

About Genome Canada

Genome Canada is a not-for-profit corporation that acts as the primary funding and information resource relating to genomics in Canada. Its main objective is to position Canada as a world leader in genomics research. Dedicated to developing and implementing a national strategy in genomics research for the benefit of all Canadians, it has received $915 million in funding from the Government of Canada since 2000 to which has been added close to $1.0 billion in partnered co-funding and interest earnings.

Contact Information